Filip Janku - Sep 13, 2024 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role
Chief Medical Officer
Signature
/s/ Markus Warmuth, Attorney-in-Fact
Stock symbol
GLUE
Transactions as of
Sep 13, 2024
Transactions value $
$0
Form type
4
Date filed
9/13/2024, 04:30 PM
Previous filing
Jan 4, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GLUE Stock Option (Right to Buy) Award $0 +30K $0.00 30K Sep 13, 2024 Common Stock 30K $7.56 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On October 3, 2022, the Reporting Person was granted an option to purchase 30,000 shares of Common Stock, subject to the satisfaction of certain performance criteria. On September 13, 2024, the performance criteria underlying such shares were met.
F2 The shares underlying this option shall vest in full on March 13, 2026, subject to the Reporting Person's continued service on such date.